Risk of COVID-19 infection in long-term survivors of blood or marrow transplantation: a BMTSS report.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
27 Jun 2023
27 Jun 2023
Historique:
accepted:
17
01
2023
received:
15
12
2022
medline:
19
6
2023
pubmed:
2
2
2023
entrez:
1
2
2023
Statut:
ppublish
Résumé
There is limited information regarding COVID-19 in long-term blood or marrow transplant (BMT) survivors. We leveraged the BMT Survivor Study (BMTSS) to address this gap. BMTSS included patients who underwent BMT at 1 of 3 sites in the United States between 1974 and 2014 and survived ≥2 years after BMT. A sibling cohort serves as a non-BMT comparison group. Participants (2430 BMT survivors; 780 non-BMT participants) completed the BMTSS survey between October 2020 and November 2021 about COVID-19 testing, risk mitigation behaviors, morbidity, and health care use. Median age at BMT was 46 years (range, 0-78 years) and median follow-up since BMT was 14 years (6-46 years); 76% were non-Hispanic White, 54% had received allogeneic BMT. The risk of COVID-19 infection was comparable for BMT survivors vs non-BMT participants (15-month cumulative incidence, 6.5% vs 8.1%; adjusted odd ratio [aOR] = 0.93; 95% confidence interval [CI], 0.65-1.33; P = .68). Among survivors, being unemployed (aOR 1.90; 95% CI, 1.12-3.23; P = .02; reference: retired) increased the odds of infection; always wearing a mask in public was protective (aOR = 0.49; 95% CI, 0.31-0.77; P = .002; reference: not always masking). When compared with COVID-positive non-BMT participants, COVID-positive BMT survivors had higher odds of hospitalization (aOR = 2.23; 95% CI, 0.99-5.05; P = .05); however, the odds of emergency department visits were comparable (aOR = 1.60; 95% CI = 0.71-3.58; P = .25). COVID-19 infection status did not increase the odds of hospitalization among BMT survivors (aOR = 1.32; 95% CI = 0.89-1.95; P = .17) but did increase the odds of emergency department visits (aOR = 2.63; 95% CI, 1.74-3.98; P <.0001). These findings inform health care providers about the management of care for long-term BMT survivors during the ongoing pandemic.
Identifiants
pubmed: 36724527
pii: 494291
doi: 10.1182/bloodadvances.2022009550
pmc: PMC9906674
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2843-2854Subventions
Organisme : NCI NIH HHS
ID : R01 CA078938
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA213140
Pays : United States
Informations de copyright
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Ann Intern Med. 2021 Mar;174(3):362-373
pubmed: 33253040
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Blood. 2010 Oct 28;116(17):3129-39; quiz 3377
pubmed: 20656930
Transpl Infect Dis. 2022 Apr;24(2):e13792
pubmed: 35030267
BMJ Open. 2020 Aug 11;10(8):e039849
pubmed: 32784264
Bone Marrow Transplant. 2015 Sep;50(9):1227-34
pubmed: 26052909
Biol Blood Marrow Transplant. 2013 Jul;19(7):1073-80
pubmed: 23583827
J Clin Oncol. 2021 Dec 1;39(34):3778-3788
pubmed: 34694886
JAMA Netw Open. 2022 Mar 1;5(3):e221754
pubmed: 35262712
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
BMC Public Health. 2022 Jul 28;22(1):1436
pubmed: 35902818
Transplant Cell Ther. 2022 Nov;28(11):737-746
pubmed: 35902050
JAMA Pediatr. 2021 Feb 1;175(2):176-184
pubmed: 33226415
Bone Marrow Transplant. 2000 Jun;25(11):1191-6
pubmed: 10849532
Nat Rev Immunol. 2021 May;21(5):277-291
pubmed: 33097917
J Psychosoc Oncol. 2021;39(3):347-365
pubmed: 33624572
J Clin Oncol. 2022 May 1;40(13):1414-1427
pubmed: 35286152
J Natl Cancer Inst. 2021 Jun 1;113(6):691-698
pubmed: 33031532
J Clin Oncol. 2022 Apr 20;40(12):1281-1290
pubmed: 35226549
Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501
pubmed: 23906634
J Am Geriatr Soc. 2022 May;70(5):1314-1324
pubmed: 35211958
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
MMWR Morb Mortal Wkly Rep. 2020 Sep 11;69(36):1250-1257
pubmed: 32915166
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
Transplant Cell Ther. 2022 Oct;28(10):696.e1-696.e7
pubmed: 35798233
Lancet Oncol. 2021 Oct;22(10):1416-1426
pubmed: 34454651
JAMA Oncol. 2022 Jan 1;8(1):69-78
pubmed: 34709356
Pediatr Blood Cancer. 2021 Mar;68(3):e28857
pubmed: 33355979